Bradley J Beattie
Overview
Explore the profile of Bradley J Beattie including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
1014
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mahajan S, Grkovski M, Staton K, Ravassa S, Domfe K, Strauss H, et al.
Clin Transl Imaging
. 2025 Feb;
12(6):619-627.
PMID: 39935517
Background: The small molecule radiotracer I-PU-H71 is an imaging biomarker of epichaperome formation. The tracer has been established to localize in tissues under chronic stress, specifically in cancer cells and...
2.
3.
Beattie B, Kirov A, Kesner A
Med Phys
. 2023 Nov;
51(3):2306-2310.
PMID: 37956259
Background: Glass Y microspheres are produced with known radionuclide impurities. These impurities are not independently monitored. Clinical instruments, including ionization chamber dose calibrators and positron emmission tomography (PET) cameras, can...
4.
Hasson A, Jiang W, Benabdallah N, Lu P, Longtine M, Beattie B, et al.
Cancer Biother Radiopharm
. 2022 Sep;
38(1):15-25.
PMID: 36149725
The majority of radiopharmaceuticals for use in disease detection and targeted treatment undergo a single radioactive transition (decay) to reach a stable ground state. Complex emitters, which produce a series...
5.
Beattie B, Akhurst T, Augensen F, Humm J
PLoS One
. 2022 Apr;
17(4):e0266704.
PMID: 35446848
Purpose: To devise a new body-habitus normalizer to be used in the calculation of an SUV that is specific to the PET tracer 18F-FDG. Methods: A cohort of 481-patients was...
6.
Bolaender A, Zatorska D, He H, Joshi S, Sharma S, Digwal C, et al.
Nat Commun
. 2021 Aug;
12(1):4669.
PMID: 34344873
Diseases are a manifestation of how thousands of proteins interact. In several diseases, such as cancer and Alzheimer's disease, proteome-wide disturbances in protein-protein interactions are caused by alterations to chaperome...
7.
Fanchon L, Beattie B, Pentlow K, Larson S, Humm J
EJNMMI Phys
. 2021 Jul;
8(1):50.
PMID: 34250566
Background: The goal of this work was to determine the quantitative accuracy and optimal reconstruction parameters for I-PET imaging in the presence of therapeutic levels of I. In this effort,...
8.
Krebs S, ODonoghue J, Biegel E, Beattie B, Reidy D, Lyashchenko S, et al.
Eur J Nucl Med Mol Imaging
. 2020 May;
47(13):3047-3057.
PMID: 32378020
Purpose: Paired imaging/therapy with radiolabeled somatostatin receptor (SSTR) antagonists is a novel approach in neuroendocrine tumors (NETs). The aim of this study was to compare tumor uptake of Ga-DOTA-JR11 and...
9.
Dunphy M, Pressl C, Pillarsetty N, Grkovski M, Modi S, Jhaveri K, et al.
Clin Cancer Res
. 2020 May;
26(19):5178-5187.
PMID: 32366671
Purpose: I-PU-H71 is an investigational first-in-class radiologic agent specific for imaging tumor epichaperome formations. The intracellular epichaperome forms under cellular stress and is a clinically validated oncotherapeutic target. We conducted...
10.
Krebs S, Veach D, Carter L, Grkovski M, Fornier M, Mauro M, et al.
J Nucl Med
. 2020 Mar;
61(11):1580-1587.
PMID: 32169913
We developed a first-of-kind dasatinib-derivative imaging agent, F-SKI-249380 (F-SKI), and validated its use for noninvasive in vivo tyrosine kinase-targeted tumor detection in preclinical models. In this study, we assessed the...